Skip to main content
Atrás
Watch Compare

SAB Biotherapeutics, Inc.

Calidad de datos: 100%
También listada como SABSW NASDAQ
SABS
NASDAQ Manufacturing Chemicals
$3.90
▲ $0.15 (4.00%)
Cap. Mercado: 268.80 M
Precio
$3.83
Cap. Mercado
268.80 M
Rango del Día
—
Rango de 52 Semanas
—
Volumen
—
Apertura —
Promedio 50D / 200D
—
Promedio 50D / 200D
—

Quick Summary

Puntos Clave

ROE of 14.99% — decent returns on equity
Negative free cash flow of -45.71 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
14.99%
Above sector avg (-54.47%)
ROIC-50.96%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio10.50
Interest Coverage-203.41

Valoración

PE (TTM|NTM)
20.25 | -11.36
Above sector avg (-1.49)
P/B Ratio1.63
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1385 pares)
Métrica Acción Mediana del Sector
P/E 20.3 -1.5
P/B 1.6 1.6
ROE % 15.0 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.7
D/E — 0.3

Precio Objetivo de Analistas

8 analistas
Buy
Actual
$3.90
+143.6%
Objetivo
$9.50
$6.00
$7.00
$15.00
Pronóstico
P/E Futuro -11.36
EPS Futuro -$0.33
Ingresos Est. 83,330.0

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 -$0.33
-$0.33 – -$0.33
 83,330.0 1
FY2026 -$0.30
-$0.30 – -$0.30
 0.0 1

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.17 -$0.41 -142.1%
Q32025 -$0.46 $0.50 +209.1%
Q22025 -$0.80 -$1.09 -36.9%
Q12025 -$1.07 -$0.56 +47.8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) 13.27 M
ROE 14.99% ROA 12.43%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -45.71 M
ROIC -50.96% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 10.50
Interest Coverage -203.41 Asset Turnover 0.00
Working Capital 102.48 M Tangible Book Value 165.07 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 20.25 Forward P/E -11.36
P/B Ratio 1.63 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 3225.78 Fwd Earnings Yield N/A
FCF Yield -17.00%
Market Cap 268.80 M Enterprise Value 239.38 M
Per Share
EPS (Diluted TTM) -0.79 Revenue / Share 0.00
FCF / Share -0.65 OCF / Share -0.64
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion -344.35%
SBC-Adj. FCF -48.80 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Revenue 0.0 1.32 M 2.24 M 23.90 M —
Net Income 13.27 M -34.11 M -42.19 M -18.74 M -8,996.0
EPS (Diluted) -0.79 -3.68 -7.64 — —
Gross Profit — — — — —
Operating Income -48.95 M -42.91 M -38.08 M -28.92 M —
EBITDA — — — — —
R&D Expenses 34.35 M 30.25 M 16.52 M 36.44 M —
SG&A Expenses — — — — —
D&A 2.99 M 4.71 M 3.65 M 3.17 M —
Interest Expense 240,664.0 318,401.0 315,284.0 301,584.0 —
Income Tax 0.0 0.0 0.0 25,629.0 —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2020
Total Assets 172.81 M 44.20 M 83.94 M 50.90 M 322,205.0
Total Liabilities 21.32 M 18.23 M 26.64 M 19.85 M —
Shareholders' Equity 151.49 M 25.97 M 57.30 M 31.06 M 16,004.0
Total Debt — — — — —
Cash & Equivalents 10.50 M 8.90 M 56.57 M 15.05 M —
Current Assets 101.05 M 23.79 M 58.91 M 22.10 M 87,094.0
Current Liabilities 10.68 M 7.98 M 10.81 M 14.99 M 306,201.0